- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 143532, 14 pages
Pre- and Postsynaptic Dopamine SPECT in Idiopathic Parkinsonian Diseases: A Follow-Up Study
1Department of Radiation Sciences, Diagnostic Radiology, Umeå University, 90187 Umeå, Sweden
2Department of Pharmacology and Clinical Neuroscience, Neurology, Umeå University, 90187 Umeå, Sweden
3Department of Statistics, Umeå School of Business and Economics, Umeå University, 90187 Umeå, Sweden
4Department of Radiation Sciences, Radiation Physics, Umeå University, 90187 Umeå, Sweden
Received 17 April 2013; Revised 2 August 2013; Accepted 8 August 2013
Academic Editor: Toshiyuki Sawaguchi
Copyright © 2013 Susanna Jakobson Mo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- W. Poewe and G. Wenning, “The differential diagnosis of Parkinson’s disease,” European Journal of Neuroscience, vol. 9, pp. 23–30, 2002.
- A. J. Hughes, S. E. Daniel, and A. J. Lees, “Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease,” Neurology, vol. 57, no. 8, pp. 1497–1499, 2001.
- A. J. Hughes, S. E. Daniel, Y. Ben-Shlomo, and A. J. Lees, “The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service,” Brain, vol. 125, no. 4, pp. 861–870, 2002.
- D. W. Dickson, “Parkinson’s disease and parkinsonism: neuropathology,” Cold Spring Harbor Perspectives in Medicine, vol. 2, no. 8, p. a009258, 2012.
- A. M. Catafau, E. Tolosa, P. Laloux et al., “Impact of dopamine transporter SPECT using123I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes,” Movement Disorders, vol. 19, no. 10, pp. 1175–1182, 2004.
- A. Loøkkegaard, L. M. Werdelin, and L. Friberg, “Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand,” European Journal of Nuclear Medicine, vol. 29, no. 12, pp. 1623–1629, 2002.
- A. M. M. Vlaar, M. J. P. G. van Kroonenburgh, A. G. H. Kessels, and W. E. J. Weber, “Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes,” BMC Neurology, vol. 7, article 27, 2007.
- C. Videbaek, K. Toska, M. A. Scheideler, O. B. Paulson, and G. Moos Knudsen, “SPECT tracer [(123)I]IBZM has similar affinity to dopamine D2 and D3 receptors,” Synapse, vol. 38, pp. 338–342, 2000.
- D. J. Burn and E. Jaros, “Multiple system atrophy: cellular and molecular pathology,” Journal of Clinical Pathology, vol. 54, no. 6, pp. 419–426, 2001.
- J. Hierholzer, M. Cordes, S. Venz et al., “Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes,” Journal of Nuclear Medicine, vol. 39, no. 6, pp. 954–960, 1998.
- Y. J. Kim, M. Ichise, J. R. Ballinger et al., “Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP,” Movement Disorders, vol. 17, no. 2, pp. 303–312, 2002.
- M. Plotkin, H. Amthauer, S. Klaffke et al., “Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients,” Journal of Neural Transmission, vol. 112, no. 5, pp. 677–692, 2005.
- A. M. M. Vlaar, T. De Nijs, A. G. H. Kessels et al., “Diagnostic value of 123I-ioflupane and 123I- iodobenzamide SPECT scans in 248 patients with Parkinsonian syndromes,” European Neurology, vol. 59, no. 5, pp. 258–266, 2008.
- S. Hellwig, F. Amtage, A. Kreft, R. Buchert, O. H. Winz, W. Vach, et al., “[18F]FDG-PET is superior to [123I]IBZM-SPECT for the differential diagnosis of parkinsonism,” Neurology, vol. 79, pp. 1314–1322, 2012.
- W. Pirker, S. Djamshidian, S. Asenbaum et al., “Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal β-CIT SPECT study,” Movement Disorders, vol. 17, no. 1, pp. 45–53, 2002.
- M. Nocker, K. Seppi, E. Donnemiller et al., “Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy: a voxel-based analysis of [123I]β-CIT SPECT,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 38, pp. 1012–1020, 2012.
- J. Linder, H. Stenlund, and L. Forsgren, “Incidence of Parkinson's disease and Parkinsonism in northern Sweden: a population-based study,” Movement Disorders, vol. 25, no. 3, pp. 341–348, 2010.
- S. Gilman, P. A. Low, N. Quinn et al., “Consensus statement on the diagnosis of multiple system atrophy,” Journal of the Neurological Sciences, vol. 163, no. 1, pp. 94–98, 1999.
- I. Litvan, Y. Agid, D. Calne et al., “Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP International Workshop,” Neurology, vol. 47, no. 1, pp. 1–9, 1996.
- W. R. G. Gibb and A. J. Lees, “The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease,” Journal of Neurology Neurosurgery and Psychiatry, vol. 51, no. 6, pp. 745–752, 1988.
- C. L. Tomlinson, R. Stowe, S. Patel, C. Rick, R. Gray, and C. E. Clarke, “Systematic review of levodopa dose equivalency reporting in Parkinson's disease,” Movement Disorders, vol. 25, no. 15, pp. 2649–2653, 2010.
- S. J. Mo, J. Linder, L. Forsgren, A. Larsson, L. Johansson, and K. Riklund, “Pre- and postsynaptic dopamine SPECT in the early phase of idiopathic parkinsonism: a population-based study,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 11, pp. 2154–2164, 2010.
- A. Larsson, S. J. Mo, and K. Riklund, “Rotation radius dependence of 123I-FP-CIT and 123I-IBZM SPECT uptake ratios: a Monte Carlo study,” Journal of Nuclear Medicine Technology, vol. 40, pp. 249–254, 2012.
- M. Oh, J. S. Kim, J. Y. Kim et al., “Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy,” Journal of Nuclear Medicine, vol. 53, no. 3, pp. 399–406, 2012.
- G. Alves, J. P. Larsen, M. Emre, T. Wentzel-Larsen, and D. Aarsland, “Changes in motor subtype and risk for incident dementia in Parkinson's disease,” Movement Disorders, vol. 21, no. 8, pp. 1123–1130, 2006.
- G. M. Halliday, J. L. Holton, T. Revesz, and D. W. Dickson, “Neuropathology underlying clinical variability in patients with synucleinopathies,” Acta Neuropathologica, vol. 122, no. 2, pp. 187–204, 2011.
- T. Brucke, S. Djamshidian, G. Bencsits, W. Pirker, S. Asenbaum, and I. Podreka, “SPECT and PET imaging of the dopaminergic system in Parkinson's disease,” Journal of Neurology, Supplement, vol. 247, supplement 4, pp. 2–7, 2000.
- E. Van Royen, N. F. L. G. Verhoeff, J. D. Speelman, E. C. Wolters, M. A. Kuiper, and A. G. M. Janssen, “Multiple system atrophy and progressive supranuclear palsy: diminished striatal D2 dopamine receptor activity demonstrated by123I-IBZM single photon emission computed tomography,” Archives of Neurology, vol. 50, no. 5, pp. 513–516, 1993.
- C. C. P. Verstappen, B. R. Bloem, C. A. Haaxma, W. J. G. Oyen, and M. W. Horstink, “Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson's disease: an [123I]IBZM and [123I]FP-CIT SPECT study,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 34, no. 4, pp. 502–507, 2007.
- E. Bezard, S. Dovero, C. Prunier et al., “Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease,” Journal of Neuroscience, vol. 21, no. 17, pp. 6853–6861, 2001.
- J. B. Schulz, T. Klockgether, D. Petersen et al., “Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT,” Journal of Neurology Neurosurgery and Psychiatry, vol. 57, no. 9, pp. 1047–1056, 1994.
- D. J. Brooks, V. Ibanez, G. V. Sawle et al., “Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography,” Annals of Neurology, vol. 31, no. 2, pp. 184–192, 1992.
- D. J. Brooks, “Diagnosis and management of atypical Parkinsonian syndromes,” Neurology in Practice, vol. 72, no. 1, pp. i10–i16, 2002.
- N. Quinn, “Multiple system atrophy: the nature of the beast,” Journal of Neurology Neurosurgery and Psychiatry, vol. 52, pp. 78–89, 1989.
- K. Fuxe, S. Ferré, S. Genedani, R. Franco, and L. F. Agnati, “Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function,” Physiology and Behavior, vol. 92, no. 1-2, pp. 210–217, 2007.
- S. Ferré, C. Quiroz, M. Orru, X. Guitart, G. Navarro, A. Cortés, et al., “Adenosine A(2A) Receptors and A(2A) Receptor Heteromers as Key Players in Striatal Function,” Frontiers in Neuroanatomy, vol. 5, article 36, 2011.
- S. Ferre, G. Von Euler, B. Johansson, B. B. Fredholm, and K. Fuxe, “Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 16, pp. 7238–7241, 1991.
- N. Nevalainen, S. Af Bjerkén, M. Lundblad, G. A. Gerhardt, and I. Strömberg, “Dopamine release from serotonergic nerve fibers is reduced in L-DOPA-induced dyskinesia,” Journal of Neurochemistry, vol. 118, no. 1, pp. 12–23, 2011.
- T. Chotibut, D. M. Apple, R. Jefferis, and M. F. Salvatore, “Dopamine transporter loss in 6-OHDA Parkinson's model is unmet by parallel reduction in dopamine uptake,” PLoS ONE, vol. 7, Article ID e52322, 2012.
- C. Scherfler, K. Seppi, E. Donnemiller et al., “Voxel-wise analysis of [123I]β-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease,” Brain, vol. 128, no. 7, pp. 1605–1612, 2005.
- E. E. Benarroch, A. M. Schmeichel, P. A. Low, and J. E. Parisi, “Involvement of medullary serotonergic groups in multiple system atrophy,” Annals of Neurology, vol. 55, no. 3, pp. 418–422, 2004.
- M. Tada, A. Kakita, Y. Toyoshima et al., “Depletion of medullary serotonergic neurons in patients with multiple system atrophy who succumbed to sudden death,” Brain, vol. 132, no. 7, pp. 1810–1819, 2009.
- K. Sato, R. Kaji, S. Matsumoto, S. Nagahiro, and S. Goto, “Compartmental loss of striatal medium spiny neurons in multiple system atrophy of Parkinsonian type,” Movement Disorders, vol. 22, no. 16, pp. 2365–2370, 2007.
- A. J. Hughes, S. E. Daniel, L. Kilford, and A. J. Lees, “Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases,” Journal of Neurology Neurosurgery and Psychiatry, vol. 55, no. 3, pp. 181–184, 1992.